Moving Towards Personalized Medicine in Rheumatoid Arthritis - Methotrexate Intracellular Pathways and Phase II Reactions as Pharmacogenetic Predictors of Methotrexate Therapeutic Outcome by Áurea Rosa Nunes Pereira Lima
 
  
 
DISSERTAÇÃO  
MESTRADO INTEGRADO EM MEDICINA 
  
Artigo de Investigação Médica 
 
 
 
 
 
Moving Towards Personalized Medicine in  
Rheumatoid Arthritis 
Methotrexate Intracellular Pathways and Phase II Reactions as 
Pharmacogenetic Predictors of Methotrexate Therapeutic Outcome  
 
 
 
 
 
 
 
ÁUREA ROSA NUNES PEREIRA LIMA  
 
 
Porto 2016 
ÁUREA ROSA NUNES PEREIRA LIMA 
 
 
 
 
Moving Towards Personalized Medicine in  
Rheumatoid Arthritis 
Methotrexate Intracellular Pathways and Phase II Reactions as 
Pharmacogenetic Predictors of Methotrexate Therapeutic Outcome  
 
 
 
 
 
 
 
Dissertação de Mestrado Integrado em Medicina submetida 
ao Instituto de Ciências Biomédicas Abel Salazar da 
Universidade do Porto. 
 
 
 
Orientador: Rui Manuel de Medeiros Melo Silva, PhD 
Categoria: Professor Associado 
Afiliação: Instituto de Ciências Biomédicas Abel Salazar - 
Universidade do Porto 
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NOTA PRELIMINAR 
Declara-se, como comunicação do papel do aluno na execução desta 
dissertação, que o autor participou da conceção e execução do trabalho experimental 
que deu origem aos resultados, bem como realizou a análise, a interpretação e a 
elaboração do documento integrante da presente dissertação. O autor escreveu ainda 
a introdução, a discussão e as conclusões, descritas no presente documento, 
salvaguardando todas as correções e recomendações providenciadas pelo seu 
orientador. 
O trabalho de investigação foi realizado no Grupo de Oncologia Molecular e 
Patologia Viral do Centro de Investigação do Instituto Português de Oncologia do 
Porto, em colaboração com o Instituto Universitário de Ciências da Saúde e o Centro 
Hospitalar de São João. 
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PREFÁCIO DO AUTOR 
No âmbito da Unidade Curricular “Dissertação/Projeto/Relatório de Estágio” do 
Mestrado Integrado em Medicina do Instituto de Ciências Biomédica Abel Salazar – 
Universidade do Porto, foi proposta a elaboração de uma Dissertação, Projeto ou 
Relatório de Estágio. De entre as três modalidades possíveis, o autor optou pela 
elaboração de uma Dissertação, mais precisamente na forma de artigo de 
investigação médica.  
Pelo exposto, o presente documento apresenta o artigo de investigação 
médica, intitulado “Moving Towards Personalized Medicine in Rheumatoid Arthritis: 
Methotrexate Intracellular Pathways and Phase II Reactions as Pharmacogenetic 
Predictors of Methotrexate Therapeutic Outcome”, cumprindo as regras da revista de 
referência “Pharmacogenomics” da Future Medicine, à qual o artigo foi submetido a 
13 de abril de 2016, encontrando-se neste momento “sob revisão”.  
Mais ainda, e porque o presente trabalho de investigação surge na sequência 
de outros já publicados pelo autor, nos quais a população alvo de estudo se encontra 
devidamente descrita, o artigo de investigação médica aqui apresentado remete para 
outras publicações do autor quando este entende ser necessário. Todavia, e para 
facilidade de leitura desta Dissertação, a descrição da população alvo de estudo 
encontra-se como Anexo no presente documento.   
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RESUMO CIRCUNSTANCIADO DA DISSERTAÇÃO 
A artrite reumatoide é uma doença autoimune, caracterizada pela inflamação 
crónica de múltiplas articulações, condicionando considerável incapacidade. O 
metotrexato é o fármaco antirreumático modificador da doença de primeira linha no 
tratamento da artrite reumatoide, devido à boa relação custo-efetividade. Não 
obstante, a variabilidade observada no perfil de resposta terapêutica (Figura 1) é uma 
realidade, pelo que esforços têm sido realizados no sentido da identificação de 
preditores genéticos de resultados negativos da medicação ao metotrexato, mais 
precisamente preditores da ocorrência de não efetividade e/ou de reações adversas, 
a fim de personalizar e otimizar a terapêutica a instituir e, desde modo, contribuir para 
mais e melhor Saúde dos doentes com artrite reumatoide.  
 
  
Figura 1. Fatores influenciadores do Perfil de Resposta Terapêutica. 
 
Neste sentido, polimorfismos genéticos em genes codificantes de proteínas 
envolvidas no mecanismo de ação do metotrexato (Figura 2) têm sido estudados, não 
havendo, à data, dados relativos à população Portuguesa.  
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Pelo exposto, o presente trabalho visa analisar a influência de um conjunto de 
polimorfismos genéticos em genes codificantes de proteínas intervenientes nas vias 
intracelulares do metotrexato como potenciais preditores da ocorrência de resultados 
negativos da medicação em doentes Portugueses com artrite reumatoide tratados 
com metotrexato. 
 
Pertinência do objeto da investigação 
Com base no conhecimento atual na área da Farmacogenómica e da 
Medicina/Terapêutica Personalizada, o trabalho a é pioneiro no que respeita à 
avaliação da influência de um conjunto alargado de polimorfismos genéticos, em 
genes codificantes para proteínas envolvidas no mecanismo de ação do metotrexato, 
como potenciais preditores de resultados negativos da medicação.  
O facto de poder vir a ser possível predizer, recorrendo ao património genético 
dos doentes com artrite reumatoide, quais aqueles que não beneficiarão do 
tratamento com metotrexato antes de iniciarem a terapêutica com o fármaco em 
causa, revela-se promissor e de extrema utilidade na prática clínica, permitindo que 
outras estratégias terapêuticas, mais efetivas e seguras, possam ser equacionadas 
mais precocemente.  
 
Materiais e métodos utilizados 
Foi realizado um estudo retrospetivo num coorte de 233 doentes com artrite 
reumatoide e sob terapêutica com metotrexato, recrutados consecutivamente na 
consulta de Reumatologia do Centro Hospitalar de São João, EPE, entre janeiro de 
2009 e dezembro de 2012, tendo por base um conjunto de critérios de 
inclusão/exclusão. Vinte variáveis clínico-patológicas foram colhidas dos registos 
clínicos individuais dos doentes. Após esclarecimento do estudo em causa e 
assinatura do consentimento informado por parte dos doentes, foram colhidas 
amostras de sangue total para posterior genotipagem de 35 polimorfismos genéticos 
em 14 genes codificantes de enzimas envolvidas em reações de fase II e de proteínas 
envolvidas em vias intracelulares do MTX, mais precisamente das vias da síntese de 
novo de purinas, dos folatos, da metionina e da adenosina. 
Para cada doente foi definido o perfil de resposta terapêutica ao metotrexato 
atendendo a critérios clínicos descritos na literatura. A análise estatística realizada 
incluiu análises uni e multivariada (regressão logística binária ajustada a variáveis 
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clínico-patológicas potencialmente influenciadoras do perfil de resposta terapêutico), 
atendendo a genótipos, haplótipos e índices de risco genético. 
 
Resultados e Conclusões 
A amostra estudada revelou-se homogénea relativamente à origem étnica 
(todos Caucasianos e do Norte de Portugal), à epidemiologia da doença face ao 
género (2-4 vezes mais prevalente nas mulheres), à idade de diagnóstico da doença 
(entre a 3ª e a 5ª década de vida), além de representativa da prática clínica de doentes 
com artrite reumatoide bem estabelecida. 
Também no que se refere ao perfil de resposta terapêutica, a amostra revelou-
se de acordo com a literatura. Verificou-se que o metotrexato foi não efetivo em 54,9% 
(n=128) e não seguro em 33,0% (n=77) dos doentes. Mais ainda, em 9,0% (n=20) foi 
simultaneamente não efetivo e não seguro; em 46,0% (n=108) foi não efetivo mas 
seguro; em 24,0% (n=57) foi efetivo mas não seguro; e, em apenas 21,0% (n=48) dos 
doentes foi simultaneamente efetivo e seguro.  
No que respeita à não efetividade do metotrexato, o estudo farmacogenético 
demonstrou uma associação estatisticamente significativa entre a não efetividade e 
oito genótipos: MTHFR rs1801131 AA e rs1801133 TT; MS rs1805087 AA; MTRR 
rs1801394 portadores do alelo A; ATIC rs2372536 portadores do alelo C, rs4673993 
portadores do alelo T, rs7563206 portadores do alelo T e rs12995526 portadores do 
alelo T; e, três haplótipos: CC para GGH rs3758149 e rs12681874; CGTTT para a 
combinação 1 de polimorfismos do ATIC e, CTTTC para a combinação 2 de 
polimorfismos do ATIC. (ATIC combinação 1: rs2372536, rs3821353, rs4673993, 
rs7563206 e rs12995526; ATIC combinação 2: rs2372536, rs4673993, rs7563206, 
rs12995526 e rs16853834. Mais ainda, a avaliação do índice de risco genético global 
para não efetividade demonstrou que os doentes com Índices 6-8 apresentavam um 
risco acrescido para não efetividade em cerca de 6 vezes superior, quando 
comparados com os doentes com Índices 0-5.  
Relativamente à não segurança do metotrexato, o estudo farmacogenético 
demonstrou uma associação estatisticamente significativa entre a falta de segurança 
do metotrexato e cinco genótipos: ATIC rs2372536 portadores do alelo G, rs3821353 
portadores do alelo T, rs7563206 CC e rs12995526 CC; e ADORA2A rs2267076 TT; 
e, dois haplótipos: CTTCC para a combinação 1 de polimorfismos do ATIC e, TC para 
ADORA2A rs2267076 e rs2298383. A avaliação do índice de risco genético global 
x 
 
para não segurança demonstrou que os doentes com Índices 3-4 apresentavam um 
risco acrescido para falta de segurança cerca de 7 vezes superior, quando 
comparados com os doentes com Índices 0-3. 
Concluindo, e tendo por base os resultados obtidos e aqui apresentados, o 
património genético dos doentes poderá ser útil para predizer os doentes com perfil 
de resposta terapêutica desfavorável e, assim, identificar aqueles que não 
beneficiarão do metotrexato como fármaco antirreumático modificador da doença de 
primeira linha no tratamento da artrite reumatoide. Consequentemente, estes dados 
poderão ser de grande utilidade na prática clínica orientando para a 
Medicina/Terapêutica Personalizada, com vista à obtenção de um perfil de resposta 
terapêutica simultaneamente efetivo e seguro adequado a cada doente. No entanto, 
mais estudos são necessários para validar esses resultados. 
 
Interesse, relevância e aplicabilidade dos resultados do trabalho 
O presente trabalho de investigação sugere que o património genético dos 
doentes, mais precisamente que polimorfismos genéticos em genes codificantes de 
proteínas envolvidas no mecanismo de ação de determinado fármaco, poderá ser útil 
na orientação da prática clínica e instituição de terapêutica personalizada, de forma a 
obter-se o perfil de resposta terapêutica desejado, isto é, seguro e efetivo. No trabalho 
apresentado, o modelo de doença usado foi a Artrite Reumatoide, o fármaco estudado 
foi o Metotrexato e os polimorfismos genéticos selecionados de acordo com o 
mecanismo de ação do fármaco em causa, bem como os indicadores de efetividade 
e não segurança foram os adequados à doença em estudo. Não obstante, e porque 
muitas são as doenças crónicas em que os doentes apresentam resultados negativos 
à medicação instituída, o património genético poderá auxiliar a prática clínica, pela 
orientação da terapêutica personalizada, com o objetivo de alcançar o perfil de 
resposta terapêutica ideal para muitas outras doenças, além da artrite reumatoide, e 
para muitos outros fármacos, além do metotrexato. Assim, a translação dos 
polimorfismos genéticos para a prática clínica com vista à previsão do perfil de 
resposta terapêutica dos doentes no momento do diagnóstico, orientando a estratégia 
terapêutica a seguir, poderá tornar-se uma realidade. Em suma, o interesse, 
relevância e aplicabilidade dos resultados do presente trabalho demonstram-se pela 
contribuição para o progresso da Farmacogenómica, o que será essencial para 
sustentar um avanço na área da Medicina e da Terapêutica Personalizada.  
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ABSTRACT 
 
Aims: Evaluate the potential of selected Single Nucleotide Polymorphisms (SNPs) as predictors of 
methotrexate (MTX) therapeutic outcome in rheumatoid arthritis (RA). Patients & Methods: Thirty-five 
SNPs in 14 genes involved in MTX intracellular pathways and Phase II reactions were genotyped in 
233 RA patients treated with MTX. Binary logistic regressions were performed by genotype/haplotype-
based approaches. Non-Response- and Toxicity-Genetic Risk Indexes (Non-RespGRI and ToxGRI) 
were created. Results: MTX non-response was associated to 8 genotypes and 3 haplotypes: MTHFR 
rs1801131 AA and rs1801133 TT; MS rs1805087 AA; MTRR rs1801394 A carriers; ATIC rs2372536 C 
carriers, rs4673993 T carriers, rs7563206 T carriers and rs12995526 T carriers; CC for GGH rs3758149 
and rs12681874; CGTTT for ATIC combination 1; and CTTTC for ATIC combination 2. From Overall 
Non-RespGRI patients with Indexes 6-8 had more than 6-fold increased risk for MTX non-response. 
MTX-related toxicity was associated to 5 genotypes and 2 haplotypes: ATIC rs2372536 G carriers, 
rs3821353 T carriers, rs7563206 CC and rs12995526 CC; ADORA2A rs2267076 T; CTTCC for ATIC 
combination 1; and TC for ADORA2A rs2267076 and rs2298383. From Overall ToxGRI patients with 
Indexes 3/4 had more than 7-fold increased risk for MTX-related toxicity. Conclusions: Genotyping 
may be helpful to identify which RA patients will not benefit from MTX treatment and, consequently, 
important to personalized medicine in RA. Nevertheless, further studies are required to validate these 
findings.  
 
 
Keywords: Genetic risk index; Methotrexate; Pharmacogenomics; Personalized medicine; 
Polymorphisms; Response; Rheumatoid arthritis; Therapeutic outcome; Toxicity. 
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INTRODUCTION 
 
During this century a new field has been discussed – the personalized medicine! The use of the right 
drug at the right dose and time, for the right patient, aimed to maximize the likelihood of therapeutic 
effectiveness and minimize the occurrence of adverse drug reactions (ADRs) [1]. Medicine was always 
personalized but only in this century the integration of patient genome was considered as important 
factor responsible for intra- and interpatient drug therapeutic outcome variability [2-4]. One of the major 
contributors of this development is Pharmacogenomics (PGx), which represents the use of individual 
genetic data to predict therapeutic outcome and tailor the best medical intervention to each patient [1]. 
During the past decade there has been considerable research into PGx but translating PGx knowledge 
into clinical practice is a major challenge, particularly in the case of highly complex diseases such as 
rheumatoid arthritis (RA) [5]. RA is a systemic autoimmune disease characterized by chronic 
inflammation of multiple peripheral joints for which the “gold standard” drug is methotrexate (MTX) [5-
7]. Literature suggests that RA patients’ genetic profile may have a significant role in therapeutic 
outcome variability observed among patients [8-10], particularly genes encoding proteins involved in 
RA pathophysiology and MTX action mechanism [9, 11, 12]. MTX action mechanism include: 1) MTX 
membrane transport pathways, a network of transporters which allow MTX influx and efflux, belonging 
to two major superfamilies’ - solute carriers (SLCs) and adenosine triphosphate (ATP)-binding cassette 
(ABCs) transporters [11, 13]; and, 2) MTX intracellular pathways, which include polyglutamation, folate, 
methionine, adenosine and de novo synthesis of purines and pyrimidines pathways [11, 14-17]. 
Polyglutamation pathway is responsible for MTX intracellular retention by the sequential addition (by 
folylpolyglutamate synthetase - FPGS) or removal (by γ-glutamyl hydrolase - GGH) of glutamic acid 
residues [18]. The amount of intracellular MTX polyglutamates (MTXPGs) depends on polyglutamation 
net rate [14, 19, 20]. Folate pathway, essential for providing the required folate cofactors for several 
pathways such de novo purine and pyrimidine synthesis, includes several enzymes such dihydrofolate 
reductase (DHFR), methylenetetrahydrofolate dehydrogenase 1 (MTHFD1), methenyltetrahydrofolate 
synthetase (MTHFS) and methylenetetrahydrofolate reductase (MTHFR). Methionine pathway, beyond 
other functions, is responsible for adenosine biosynthesis (via transmethylation), a potent anti-
inflammatory agent with a key role on MTX anti-inflammatory effect [21, 22]. This effect can be 
modulated by the activity of methionine synthase (MS) and methionine synthase reductase (MTRR) in 
the presence of a methyl(III)cobalamin cofactor [21, 22]. De novo synthesis of purines pathway is one 
of the most prominent for MTX therapeutic effects [8, 23] because of the involvement of several key 
proteins such as glycinamide ribonucleotide formyl transferase (GART), phosphoribosyl pyrophosphate 
amidotransferase (PPAT) and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) 
transformylase (ATIC) [23]. Literature hypothesizes that AICAR accumulation, as a consequence of 
ATIC inhibition by MTXPGs, is responsible for intracellular accumulation of adenosine and its release 
to extracellular space [8, 16]. Adenosine pathway is responsible for the other three ways of adenosine 
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biosynthesis (beyond transmethylation): 1) cyclic adenosine monophosphate (cAMP) conversion to 
adenosine [24]; 2) intracellular ATP dephosphorylation to adenosine, activated when energy demand 
exceeds energy supply [25, 26]; and 3) extracellular ATP conversion to adenosine by ectoenzymes 
cluster of differentiation (CD) 39 and CD73 [27, 28]. In vitro, in vivo and clinical data studies theorize 
that adenosine is released in high concentrations from cells by nucleoside transporters (NTs) after MTX 
treatment [16, 29], then adenosine exerts its anti-inflammatory effects on target cells via interaction with 
G-coupled adenosine receptors (ADOR): ADORA2A and ADORA3 (Figure 1) [30].  
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In addition, proteins that inactivate MTX, such glutathione S-transferase P1 (GSTP1), a Phase II 
reaction enzyme, can be also important as predictor of MTX therapeutic outcome [31]. Therefore, and 
given the importance of all MTX intracellular pathways and Phase II reactions, genetic polymorphisms 
involved in these pathways seem to be crucial targets to evaluate their potential as predictors of MTX 
therapeutic outcome. Emphasizing that present work follows up another four, where relevant results 
were obtained for MTX membrane transporters and de novo pyrimidine synthesis pathways [13, 32-
34], it is aimed to evaluate selected SNPs in genes encoding for other MTX pathways as potential 
predictors of MTX therapeutic outcome for Portuguese RA patients, hoping to bring awareness among 
scientific community about the importance of translation knowledge into clinical practice, towards 
personalized medicine. 
 
 
PATIENTS & METHODS 
 
Patients & Study Design 
This study, conducted between January 2009 and December 2012 at São João Hospital Center (Porto, 
Portugal), was developed as a retrospective study in a cohort of consecutive Caucasian patients (≥ 18 
years) with RA treated with MTX. All patients had to meet the 2010 revised classification criteria of 
American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) [35]. 
Patients were excluded if had drug abuse history, recent pregnancy or desire to become pregnant 
during the study. The study was approved by local research ethics committee (reference 33/2009) and 
informed written consent was obtained from all patients according to the standards of Helsinki 
Declaration. 
Therapeutic strategy: All patients were initially treated with 10mg per os (PO)/week of MTX in 
monotherapy. This dose was increased 5mg at each 3 weeks if patients did not meet EULAR criteria 
for response, i.e. if presented a Disease Activity Score in 28 joints (DAS28) >3.2. Every 3 months MTX 
clinical response was evaluated and therapeutic strategies were defined as follow: 1) first evaluation, if 
patients have no response or show gastrointestinal toxicity, administration route was changed to 
subcutaneous (SC); 2) second evaluation, if maximum tolerable dose was used without response, MTX 
therapy was discontinued or associated with other synthetic disease modifying anti-rheumatic drug 
(DMARD); and 3) third evaluation, in patients without response and other contraindication, therapy was 
changed by associating a biological DMARD. Folic acid supplementation was prescribed to all patients 
and its regular compliance was registered. Other concomitant drugs, such as corticosteroids, non-
steroidal anti-inflammatory drugs (NSAIDs), and other DMARDs were allowed during the study.  
Data collection and variable definition: Patient demographics, clinicopathological and treatment 
characteristics were collected from clinical records. MTX clinical response was recorded at each visit 
and assessed using the DAS28. Estimated glomerular filtration rate (eGFR) was calculated using the 
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follow Modification of Diet in Renal Disease (MDRD) equation: 186x(creatinine/88.4)-1.154x(Age)-
0.203x(0.742 if female)x(1.210 if black).  
Outcome definition: Clinical response to MTX. Non-response was defined when patients presented 
a DAS28 >3.2, calculated and defined as described by Prevoo et al. [36], in two consecutive 
evaluations. Therefore, non-response to MTX was defined only after a minimum period of at least 6 
months of MTX therapy. Response to MTX was defined when patients presented a DAS28 ≤3.2. MTX-
related toxicity. The occurrence of MTX-related toxicity, defined when patients presented any ADR 
related to MTX, was recorded upon each visit. ADR type was classified in System Organ Class (SOC) 
disorders, in accordance with Common Terminology Criteria for Adverse Events (CTCAE) [37].  
 
SNPs Selection & Genotyping 
A total of 35 SNPs in 14 genes encoding for proteins involved in MTX intracellular pathways and Phase 
II reactions were selected based on literature, attending to their putative effects on proteins activity 
and/or MTX therapeutic outcome [4, 9, 10, 19, 38-48]. Whole blood samples from each patient were 
obtained with standard venipuncture technique. Genomic DNA was extracted with QIAamp DNA Blood 
Mini Kit (QIAGEN, Hilden, Germany) according to manufacturer instructions and total genomic DNA 
was quantified, and its purity analyzed using NanoDrop 1000 Spectrophotometer v3.7 (Thermo 
Scientific, Wilmington DE, USA). Sequenom® Assay Design 3.1 software was used to primers design 
and genotyping was performed according to standard Sequenom® iPLEX protocol [49]. For quality 
control, 10% of the samples were randomly selected for a second analysis and results were 100% 
concordant.  
 
Statistical Analysis  
Statistical analysis was performed with either IBM® SPSS® Statistics for Windows, Version 20.0 (IBM 
Corp, Armonk, NY, USA) and SNPStats software [50]. Genotype frequencies were assessed and tested 
for Hardy-Weinberg equilibrium (HWE). SNPs were excluded from analysis when genotyping call rates 
were less than 95% and when minor allele frequency was less than 10.0%. Haplotype analysis was 
performed to assess possible consequences on the phenotype by the co-presence of several variants 
of the same gene. Linkage disequilibrium (LD) between SNPs in same gene was estimated and 
expressed as D´ coefficients.  
Multivariate analyses by binary logistic regression were used to compare genotypes and haplotypes 
with MTX therapeutic outcome. Binary logistic regression was adjusted to clinicopathological variables 
possibly influencing disease state and/or clinical response to MTX. Such variables were selected based 
either in literature review and/or clinical significance [38, 51-54] and included the following variables: 1) 
patient-related: age, gender, smoking status and renal function (eGFR and serum creatinine – SCr); 2) 
disease-related: diagnosis age and disease duration; and, 3) treatment-related: folic acid, 
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corticosteroids, NSAIDs, other DMARDs and MTX administration characteristics (dose, treatment 
duration and administration route). Possible haplotypes were tested for association with MTX 
therapeutic outcome by taking the most frequent haplotype as reference. Rare haplotypes (estimated 
haplotype frequency <2.0%) were excluded. Non-Response- and Toxicity-Genetic Risk Indexes (Non-
RespGRI and ToxGRI, respectively) were created for each pathway and for all pathways by the sum of 
risk genotypes that revealed to be statistically significant with MTX non-response and MTX-related 
toxicity. Index number was in accordance to the possible combinations between risk genotypes and 
tested for association with MTX therapeutic outcome in a binary logistic regression. Forest plots were 
constructed using MedCalc® software for Windows, Version 13.1.2 [55]. Results were expressed as 
odds ratios (OR) with 95% confidence intervals (CI) and considering a probability (p) value of 5% or 
less as statistically significant. 
 
RESULTS 
 
Patients’ Characteristics 
This study included follow-up data from 233 patients, 196 (84.1%) females and 37 (15.9%) males, with 
a mean age of 51±11.6 years old, of which 32 (13.7%) were smokers. Median of SCr was 8.20mg/L 
(4.00-19.80) and of eGFR was 82.0ml/min/1.73m2 (29.00-186.00), and 30 patients (12.9%) presented 
renal insufficiency (eGFR<60ml/min/1.73m2). Considering disease-related variables, the mean age at 
diagnosis was 40.3±13.2 years old, the median disease duration was 7.0 years (0.3-51.0) and the mean 
for DAS28 was 4.2±1.3. All patients (100.0%) were treated with MTX with a median dose of 
15.0mg/week (2.5-25.0), 118 (50.6%) complied regularly to folic acid supplementation, 188 (80.7%) 
were under corticosteroid therapy and 170 (73.0%) used NSAIDs.  
Non-response to MTX (DAS28>3.2 in two consecutive evaluations) was observed in 128 (54.9%) 
patients. MTX-related toxicity was registered in 77 (33.0%) patients. The observed ADRs were 
classified in SOCs disorders as follow: 58 (75.3%) gastrointestinal disorders (abdominal distension, 
diarrhea, dyspepsia, nauseas, stomach pain and/or vomiting); 9 (11.7%) skin and subcutaneous tissue 
disorders (alopecia, rash maculopapular and rheumatoid nodulosis exacerbation); 5 (6.5%) 
hepatobiliary disorders (determined by transaminases serum elevation); and 5 (6.5%) respiratory, 
thoracic and mediastinal disorders (hypersensitivity pneumonitis). Since the number of cases in each 
SOCs disorders were small, the evaluation of putative SNPs predictors of MTX-related toxicity 
occurrence was performed for overall toxicity.  
Genotypes and Haplotypes Characteristics 
Genotypes distribution of studied SNPs is represented in Table 1. SNPs were excluded from analysis 
when minor allele frequency was less than 10.0% and/or call rates were less than 95%: 1) FPGS 
rs10760502; 2) GGH rs1800909, rs11545076 and rs11545078; 3) DHFR rs1105525, rs1650697 and 
rs34764978; 4) PPAT rs3796548; and, 5) ADA rs73598374. Therefore, 26 SNPs were considered. 
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Genotypes distribution was in HWE (p >0.050) except for GGH rs3758149 and ATIC rs3821353. FPGS, 
GGH, DHFR, MTHFR and ADORA2A SNPs were in LD. For ATIC, SNPs were in LD except for 
rs3821353 and rs16853834. Hence analyses regarding ATIC were performed considering the following 
combinations: 1) ATIC combination 1: rs2372536, rs3821353, rs4673993, rs7563206 and rs12995526; 
and 2) ATIC combination 2: rs2372536, rs4673993, rs7563206, rs12995526 and rs16853834.  
 
Table 1. Genotypes frequency of studied SNPs  
rs ID Alleles 
Genotype frequency  
Ancestral allele 
homozygotes 
Heterozygotes Minor  allele 
homozygotes 
Polyglutamation pathway 
FPGS     
rs10106 A>G 78 (33.5) 105 (45.1) 50 (21.5) 
rs1054774 T>A  88 (37.8) 109 (46.8) 36 (15.5) 
rs1544105 G>A 78 (33.5) 110 (47.2) 45 (19.3) 
rs4451422 a) A>C 79 (34.1) 105 (45.3) 48 (20.7) 
rs10760502 # G>A  63 (40.7) 50 (32.2) 42 (27.1) 
GGH     
rs1800909 # T>C 163 (85.3) 28 (14.7) 0 (0.0) 
rs3758149 a) C>T 125 (53.9) 80 (34.5) 27 (11.6) 
rs11545076 # G>T 0 (0.0) 233 (100.0) 0 (0.0) 
rs11545078 # C>T 203 (87.1) 29 (12.4) 1 (0.4) 
rs12681874 C>T 183 (78.5) 46 (19.7) 4 (1.7) 
Folate pathway 
DHFR     
rs7387  T>A 106 (45.7) 106 (45.5) 21 (9.1) 
rs1105525 # C/G>A 0 (0.0) 0 (0.0) 0 (0.0) 
rs1232027  G>A 94 (40.3) 113 (48.5) 26 (11.2) 
rs1643657 A>G 105 (45.1) 107 (45.9) 21 (9.0) 
rs1650697 #      C>T 5 (2.1) 2 (0.9) 0 (0.0) 
rs10072026 T>C 181 (77.7) 47 (20.2) 5 (2.1) 
rs34764978 # A>G 0 (0.0) 0 (0.0) 0 (0.0) 
MTHFR     
rs1801131 A>C 126 (54.1) 85 (36.5) 22 (9.4) 
rs1801133 C>T 105 (45.1) 99 (42.5) 29 (12.4) 
MTHFS     
rs8923 A>G 184 (79.0) 46 (19.7) 3 (1.3) 
Methionine pathway 
MS     
rs1805087 A>G 158 (67.8) 70 (30.0) 5 (2.1) 
MTRR     
rs1801394 G>A 62 (26.6) 118 (50.6) 53 (22.7) 
Results are expressed as n (%). a) Genotypes technique failed to 1 patient.  # SNPs were excluded from analysis because minor allele 
frequency was <10.0% and/or call rates were <95%. 
A: adenine; ADA: adenosine deaminase; ADORA2A: adenosine receptor subtype A2A; AMPD1: adenosine monophosphate 
deaminase 1; ATIC: 5-aminoimidazole-4-carboxamide ribonucleotide transformylase; C: cytosine; DHFR: dihydrofolate reductase; 
FPGS: folylpolyglutamate synthetase; G: guanine; GART: glycinamide ribonucleotide formyl transferase; GGH: gamma-glutamyl 
hydrolase; GSTP1: human glutathione S-transferase P1; MS: methionine synthase; MTHFD1: methylenetetrahydrofolate 
dehydrogenase 1; MTHFR: methylenetetrahydrofolate reductase; MTHFS: methenyltetrahydrofolate synthetase; MTRR: methionine 
synthase reductase; PPAT: phosphoribosyl pyrophosphate amidotransferase; SHMT1: serine hydroxymethyltransferase 1; T: 
thymine. 
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Table 1. Genotypes frequency of studied SNPs (cont.) 
rs ID Alleles 
Genotype frequency   
Ancestral allele 
homozygotes 
Heterozygotes Minor  allele 
homozygotes 
De novo purines synthesis pathway     
ATIC     
rs2372536 C>G 110 (47.2) 99 (42.5) 24 (10.3) 
rs3821353 G>T 166 (71.2) 46 (19.7) 21 (9.0) 
rs4673993 T>C 110 (47.2) 99 (42.5) 24 (10.3) 
rs7563206 T>C 65 (27.9) 109 (46.8) 59 (25.3) 
rs12995526 T>C 67 (28.8) 110 (47.2) 56 (24.0) 
rs16853834 C>T 160 (68.7) 68 (29.2) 5 (2.1) 
GART     
rs8971 A>G 128 (54.9) 86 (36.9) 19 (8.2) 
PPAT     
rs3796548 # C>T 191 (82.0) 41 (17.6) 1 (0.4) 
Adenosine pathway 
ADA     
rs73598374 # G>A 0 (0.0) 0 (0.0) 0 (0.0) 
ADORA2A     
rs2267076 C>T 91 (39.1) 112 (48.1) 30 (12.9) 
rs2298383 T>C 77 (33.0) 110 (47.2) 46 (19.7) 
AMPD1     
rs17602729 C>T 180 (77.3) 48 (20.6) 5 (2.1) 
Phase II reaction 
GSTP1     
rs1695 A>G 103 (44.2) 104 (44.6) 26 (11.2) 
Results are expressed as n (%). a) Genotypes technique failed to 1 patient.  # SNPs were excluded from analysis because minor allele 
frequency was <10.0% and/or call rates were <95%. 
A: adenine; ADA: adenosine deaminase; ADORA2A: adenosine receptor subtype A2A; AMPD1: adenosine monophosphate 
deaminase 1; ATIC: 5-aminoimidazole-4-carboxamide ribonucleotide transformylase; C: cytosine; DHFR: dihydrofolate reductase; 
FPGS: folylpolyglutamate synthetase; G: guanine; GART: glycinamide ribonucleotide formyl transferase; GGH: gamma-glutamyl 
hydrolase; GSTP1: human glutathione S-transferase P1; MS: methionine synthase; MTHFD1: methylenetetrahydrofolate 
dehydrogenase 1; MTHFR: methylenetetrahydrofolate reductase; MTHFS: methenyltetrahydrofolate synthetase; MTRR: methionine 
synthase reductase; PPAT: phosphoribosyl pyrophosphate amidotransferase; SHMT1: serine hydroxymethyltransferase 1; T: 
thymine. 
 
 
Genotypes, Haplotypes, Genetic Risk Indexes & Methotrexate Therapeutic Outcome  
Polyglutamation pathway: Table 2 represents the relation between MTX therapeutic outcome and 
SNPs in FPGS and GGH by genotype- and haplotype-based approaches. Considering genotype 
approach, our results demonstrated non-statistically significantly results for FPGS (rs10106, 
rs1054774, rs1544105 and rs4451422) and GGH (rs3758149 and rs12681874). Nevertheless, CC 
haplotype for GGH rs3758149 and rs12681874 was associated with an increased risk for MTX non-
response, when compared to TC haplotype. No statistically significant associations were observed for 
haplotypes and MTX-related toxicity. 
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Table 2. Association of SNPs involved in Polyglutamation Pathway with MTX Therapeutic Outcome 
 Clinical Response Overall Toxicity 
 Response Non-response p OR (95%CI) Non-toxicity Toxicity p OR (95%CI) 
GENOTYPES 
FPGS A>G (rs10106)  
AA+AG 83 (45.4) 100 (54.6)  1.00 123 (67.2) 60 (32.8)  1.00 
GG 22 (44.0) 28 (56.0) 0.317 1.50 (0.68-3.29) 33 (66.0) 17 (34.0) 0.850 1.09 (0.46-2.59) 
AA 28 (35.9) 50 (64.1)  1.00 57 (73.1) 21 (26.9)  1.00 
AG+GG 77 (49.7) 78 (50.3) 0.070 0.51 (0.25-1.06) 99 (63.9) 56 (36.1) 0.267 1.57 (0.71-3.46) 
FPGS T>A (rs1054774)  
TT+TA 91 (46.2) 106 (53.8)  1.00 131 (66.5) 66 (33.5)  1.00 
AA 14 (38.9) 22 (61.1) 0.172 1.87 (0.76-4.57) 25 (69.4) 11 (30.6) 0.960 0.97 (0.36-2.62) 
TT 33 (37.5) 55 (62.5)  1.00 63 (71.6) 25 (28.4)  1.00 
TA+AA 72 (49.7) 73 (50.3) 0.070 0.52 (0.26-1.06) 93 (64.1) 52 (35.9) 0.507 1.29 (0.61-2.73) 
FPGS G>A (rs1544105)  
GG+GA 85 (45.2) 103 (54.8)  1.00 127 (67.6) 61 (32.4)  1.00 
AA 20 (44.4) 25 (55.6) 0.316 1.53 (0.67-3.50) 29 (64.4) 16 (35.6) 0.797 1.12 (0.46-2.76) 
GG 29 (37.2) 49 (62.8)  1.00 56 (71.8) 22 (28.2)  1.00 
GA+AA 76 (49.0) 79 (51.0) 0.115 0.56 (0.27-1.15) 100 (64.5) 55 (35.5) 0.557 1.27 (0.57-2.84) 
FPGS A>C (rs4451422)  
AA+AC 84 (45.7) 100 (54.3)  1.00 123 (66.8) 61 (33.2)  1.00 
CC 21 (43.8) 27 (56.2) 0.270 1.57 (0.70-3.49) 32 (66.7) 16 (33.3) 0.950 0.97 (0.40-2.34) 
AA 29 (36.7) 50 (63.3)  1.00 58 (73.4) 21 (26.6)  1.00 
AC+CC 76 (49.7) 77 (50.3) 0.077 0.52 (0.25-1.07) 97 (63.4) 56 (36.6) 0.192 1.70 (0.77-3.76) 
GGH C>T (rs3758149)  
CC+CT 91 (44.4) 114 (55.6)  1.00 138 (67.3) 67 (32.7)  1.00 
TT 14 (51.9) 13 (48.1) 0.169 0.47 (0.16-1.38) 17 (63.0) 10 (37.0) 0.368 1.66 (0.55-5.01) 
CC 53 (42.4) 72 (57.6)  1.00 81 (64.8) 44 (35.2)  1.00 
CT+TT 52 (48.6) 55 (51.4) 0.065 0.53 (0.27-1.04) 74 (69.2) 33 (30.8) 0.515 1.27 (0.62-2-60) 
GGH C>T (rs12681874)  
CC+CT 102 (44.5) 127 (55.5)  1.00 154 (67.2) 75 (32.8)  1.00 
TT 3 (75.0) 1 (25.0) 0.460 0.38 (0.03-4.98) 2 (50.0) 2 (50.0) 0.636 1.70 (0.19-15.21) 
CC 82 (44.8) 101 (55.2)  1.00 122 (66.7) 61 (33.3)  1.00 
CT+TT 23 (46.0) 27 (54.0) 0.703 0.86 (0.40-1.85) 34 (68.0) 16 (32.0) 0.410 0.68 (0.27-1.69) 
HAPLOTYPES 
FPGS A>G 
(rs10106) 
FPGS T>A 
(rs1054774) 
FPGS G>A 
(rs1544105) 
FPGS A>C 
(rs4451422) 
% * 
Clinical Response Overall Toxicity 
p OR (95%CI) p OR (95%CI) 
A T G A 54.7  1.00  1.00 
G A A C 38.6 0.590 0.88 (0.55-1.41) 0.610 1.15 (0.67-1.96) 
G T A C 2.75 0.600 1.50 (0.33-6.85) 0.500 1.70 (0.37-7.82) 
GGH C>T  
(rs3758149) 
GGH C>T 
(rs12681874) 
     
C C 66.0  1.00  1.00 
T C 22.4 0.037 0.50 (0.26-0.95) 0.150 1.62 (0.85-3.09) 
T T 6.4 0.740 0.84 (0.30-2.34) 0.490 0.69 (0.24-1.97) 
C T 5.1 0.440 0.65 (0.22-1.92) 0.840 1.13 (0.34-3.72) 
Results are expressed in n (%). p ≤0.05 was considered as statistically significant (highlighted in bold). Multivariate analysis was adjusted 
to following variables: 1) patient-related: age, gender, smoking status and renal function; 2) disease-related: diagnosis age and disease 
duration; and, 3) treatment-related: folic acid, corticosteroids, NSAIDs, other DMARDs and MTX administration characteristics (dose, 
treatment duration and administration route). Non-RespGRI and ToxGRI were not performed because studied genotypes for 
polyglutamation pathway did not revealed to be statistically significant with MTX therapeutic outcome. *Rare haplotypes (estimated 
haplotype frequency <2.0%) were excluded from analysis. A: adenine; C: cytosine; CI: confidence interval; DMARDs: disease modifying 
anti-rheumatic drugs; FPGS: folylpolyglutamate synthetase; G: guanine; GGH: γ-glutamyl hydrolase; MTX: methotrexate; Non-RespGRI: 
genetic risk index for non-response; NSAIDs: non-steroidal anti-inflammatory drugs; OR: odds ratio; T: thymine; ToxGRI: genetic risk index 
for MTX-toxicity. 
 
 
Folate pathway: Table 3 represents the relation between MTX therapeutic outcome and SNPs in 
DHFR, MTFHR and MTHFS by genotype-, haplotype- and genetic risk index-based approaches. 
Considering genotype approach, 2 SNPs were associated with about 2-fold increased risk for MTX non-
response: MTHFR rs1801131 A homozygotes and MTHFR rs1801133 T homozygotes. No significant 
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associations with MTX non-response were observed for DHFR polymorphisms (rs7387, rs1232027, 
rs1643657 and rs10072026) and MTHFS rs8923. Moreover, no statistically significant associations 
were observed attending to studied SNPs of folate pathway and MTX-related toxicity occurrence. 
Moreover, no associations were obtained in haplotype approach. Non-RespGRI from folate pathway 
demonstrated that patients with Index 2 (MTHFR rs1801131 AA + MTHFR rs1801133 TT) presented 
an increased risk for MTX non-response of about 5-fold when compared to those with Index 0. 
 
Table 3. Association of SNPs involved in Folate Pathway with MTX Therapeutic Outcome 
 Clinical Response Overall Toxicity 
 Response Non-response p OR (95%CI) Non-toxicity Toxicity p OR (95%CI) 
GENOTYPES 
DHFR T>A (rs7387)  
TT+TA 93 (43.9) 119 (56.1)  1.00 145 (68.4) 67 (31.6)  1.00 
AA 12 (57.1) 9 (42.9) 0.947 0.96 (0.31-2.99) 11 (52.4) 10 (47.6) 0.338 1.80 (0.54-5.98) 
TT 49 (46.2) 57 (53.8)  1.00 74 (69.8) 32 (30.2)  1.00 
TA+AA 56 (44.1) 71 (55.9) 0.078 1.84 (0.93-3.63) 82 (64.6) 45 (35.4) 0.498 1.28 (0.63-2.59) 
DHFR G>A (rs1232027)  
GG+GA 91 (44.0) 116 (56.0)  1.00 142 (68.6) 65 (31.4)  1.00 
AA 14 (53.8) 12 (46.2) 0.395 1.55 (0.57-4.25) 14 (53.8) 12 (46.2) 0.587 1.35 (0.46-4.00) 
GG 42 (44.7) 52 (55.3)  1.00 63 (67.0) 31 (33.0)  1.00 
GA+AA 63 (45.3) 76 (54.7) 0.287 1.44 (0.73-2.83) 93 (66.9) 46 (33.1) 0.968 0.98 (0.48-2.03) 
DHFR A>G (rs1643657)  
AA+AG 93 (43.9) 119 (56.1)  1.00 145 (68.4) 67 (31.6)  1.00 
GG 12 (57.1) 9 (42.9) 0.947 0.96 (0.31-2.99) 11 (52.4) 10 (47.6) 0.338 1.80 (0.54-5.98) 
AA 49 (46.7) 56 (53.3)  1.00 73 (69.5) 32 (30.5)  1.00 
AG+GG 56 (43.8) 72 (56.2) 0.066 1.89 (0.96-3.72) 83 (64.8) 45 (35.2) 0.514 1.27 (0.62-2.57) 
DHFR T>C (rs10072026)  
TT+TC 103 (45.2) 100 (54.3)  1.00 152 (66.7) 76 (33.3)  1.00 
CC 2 (40.0) 27 (56.2) 0.864 1.24 (0.11-14.43) 4 (80.0) 1 (20.0) 0.392 0.31 (0.02-4.50) 
TT 76 (42.0) 105 (58.0)  1.00 123 (68.0) 58 (32.0)  1.00 
TC+CC 29 (55.8) 23 (44.2) 0.144 0.56 (0.25-1.22) 33 (63.5) 19 (36.5) 0.452 1.37 (0.60-3.13) 
MTHFR A>C (rs1801131)  
AA+AC 93 (44.1) 118 (55.9)  1.00 144 (68.2) 67 (31.8)  1.00 
CC 12 (54.5) 10 (45.5) 0.910 1.07 (0.35-3.28) 12 (54.5) 10 (45.5) 0.761 1.22 (0.33-4.53) 
AA 48 (38.1) 78 (61.9)  1.00 91 (72.2) 35 (27.8)  1.00 
AC+CC 57 (53.3) 50 (46.7) 0.045 0.51 (0.26-0.98) a) 65 (60.7) 42 (39.3) 0.369 1.39 (0.68-2.85) 
MTHFR C>T (rs1801133)  
CC+CT 98 (48.0) 106 (52.0)  1.00 135 (66.2) 69 (33.8)  1.00 
TT 7 (24.1) 22 (75.9) 0.019 3.86 (1.25-11.89) 21 (72.4) 8 (27.6) 0.302 1.80 (0.59-5.51) 
CC 52 (49.5) 53 (50.5)  1.00 62 (59.0) 43 (41.0)  1.00 
CT+TT 53 (41.4) 75 (58.6) 0.536 1.23 (0.63-2.39) 94 (73.4) 34 (26.6) 0.373 0.72 (0.35-1.48) 
MTHFS A>G (rs8923) 
AA+AG 105 (45.7) 125 (54.3)  1.00 153 (66.5) 77 (33.5)  1.00 
GG 0 (0.0) 3 (100.0) 0.999 1.00 (1.00-1.00) 3 (100.0) 0 (0.0) 0.999 1.00 (1.00-1.00) 
AA 81 (44.0) 103 (56.0)  1.00 125 (67.9) 59 (32.1)  1.00 
AG+GG 24 (49.0) 25 (51.0) 0.657 1.19 (0.54-2.62) 31 (63.3) 18 (36.7) 0.718 1.17 (0.49-2.79) 
Results are expressed in n (%). p ≤0.05 was considered as statistically significant (highlighted in bold). Multivariate analysis was adjusted 
to following variables: 1) patient-related: age, gender, smoking status and renal function; 2) disease-related: diagnosis age and disease 
duration; and, 3) treatment-related: folic acid, corticosteroids, NSAIDs, other DMARDs and MTX administration characteristics (dose, 
treatment duration and administration route). ToxGRI was not performed because genotypes from studied SNPs for folate pathway did not 
revealed to be statistically significant with MTX-related toxicity.*Rare haplotypes (estimated haplotype frequency <2.0%) were excluded 
from analysis. a) When reference was C carriers: OR=1.96, 95%CI: 1.01-3.79. A: adenine; C: cytosine; CI: confidence interval; DHFR: 
dihydrofolate reductase; DMARDs: disease modifying anti-rheumatic drugs; G: guanine; MTHFR: methylenetetrahydrofolate reductase; 
MTHFS: methylenetetrahydrofolate synthetase; MTX: methotrexate; Non-RespGRI: genetic risk index for non-response; NSAIDs: non-
steroidal anti-inflammatory drugs; OR: odds ratio; T: thymine; ToxGRI: genetic risk index for MTX-toxicity. 
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Table 3. Association of SNPs involved in Folate Pathway with MTX Therapeutic Outcome (cont.) 
HAPLOTYPES 
DHFR T>A 
(rs7387) 
DHFR G>A 
(rs1232027) 
DHFR A>G 
(rs1643657) 
DHFR T>C 
(rs10072026) 
% * 
Clinical Response Overall Toxicity 
p OR (95%CI) p OR (95%CI) 
T G A T 50.9  1.00  1.00 
A A G T 29.0 0.310 1.34 (0.76-2.35) 0.380 1.32 (0.71-2.43) 
T G A C 10.7 0.110 0.50 (0.21-1.17) 0.150 2.01 (0.79-5.12) 
T A A T 5.9 0.990 1.01 (0.33-3.04) 0.770 1.19 (0.37-3.84) 
A G G T 2.8 0.230 2.40 (0.51-15.47) 0.260 2.56 (0.50-12.99) 
MTHFR A>C  
(rs1801131) 
MTHFR C>T  
(rs1801133) 
      
A C 38.9  1.00  1.00 
A T 33.4 0.390 1.27 (0.73-2.21) 0.770 0.91 (0.49-1.70) 
C C 27.4 0.210 0.70 (0.40-1.22) 0.890 1.05 (0.55-1.99) 
GENETIC RISK INDEXES 
Non-RespGRI 
Clinical Response 
Response Non-response p OR (95%CI) 
Index 0  rs1801131 – AC+CC AND rs1801133 – CC+CT 57 (53.3) 50 (46.7)  1.00 
Index 1 rs1801131 – AA OR rs1801133 – TT 41 (42.3) 56 (57.7) 0.197 1.58 (0.79-3.17) 
Index 2  rs1801131– AA AND rs1801133 – TT 7 (24.1) 22 (75.9) 0.009 5.23 (1.51-18.14) 
Results are expressed in n (%). p ≤0.05 was considered as statistically significant (highlighted in bold). Multivariate analysis was adjusted 
to following variables: 1) patient-related: age, gender, smoking status and renal function; 2) disease-related: diagnosis age and disease 
duration; and, 3) treatment-related: folic acid, corticosteroids, NSAIDs, other DMARDs and MTX administration characteristics (dose, 
treatment duration and administration route). ToxGRI was not performed because genotypes from studied SNPs for folate pathway did not 
revealed to be statistically significant with MTX-related toxicity.*Rare haplotypes (estimated haplotype frequency <2.0%) were excluded 
from analysis. a) When reference was C carriers: OR=1.96, 95%CI: 1.01-3.79. A: adenine; C: cytosine; CI: confidence interval; DHFR: 
dihydrofolate reductase; DMARDs: disease modifying anti-rheumatic drugs; G: guanine; MTHFR: methylenetetrahydrofolate reductase; 
MTHFS: methylenetetrahydrofolate synthetase; MTX: methotrexate; Non-RespGRI: genetic risk index for non-response; NSAIDs: non-
steroidal anti-inflammatory drugs; OR: odds ratio; T: thymine; ToxGRI: genetic risk index for MTX-toxicity. 
 
 
Methionine pathway: Table 4 represents the relation between MTX therapeutic outcome and 
polymorphisms in MS and MTRR by genotype- and genetic risk index-based approaches. The MS 
rs1805087 A homozygotes and MTRR rs1801394 A carriers were associated with about 2-fold 
increased risk for a non-response profile to MTX but demonstrated a non-significant association with 
MTX-related toxicity. Non-RespGRI from methionine pathway demonstrated that patients with Index 2 
(MS rs1805087 AA + MTRR rs1801394 A carriers) presented more than 5-fold increased risk for MTX 
non-response then those with Index 0. 
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Table 4. Association of SNPs involved in Methionine Pathway with MTX Therapeutic Outcome 
 Clinical Response Overall Toxicity 
 Response Non-response p OR (95%CI) Non-toxicity Toxicity p OR (95%CI) 
GENOTYPES 
MS A>G (rs1805087)  
AA+AG 102 (44.7) 126 (55.3)  1.00 153 (67.1) 75 (32.9)  1.00 
GG 3 (60.0) 2 (40.0) 0.247 0.27 (0.03-2.51) 3 (60.0) 2 (40.0) 0.316 2.86 (0.36-22.47) 
AA 66 (41.8) 92 (58.2)  1.00 108 (68.4) 50 (31.6)  1.00 
AG+GG 39 (52.0) 36 (48.0) 0.017 0.42 (0.20-0.86) a) 48 (64.0) 27 (36.0) 0.066 2.04 (0.95-4.39) 
MTRR G>A (rs1801394) 
GG+GA 84 (46.7) 96 (53.3)  1.00 123 (68.3) 57 (31.7)  1.00 
AA 21 (39.6) 32 (60.4) 0.046 2.36 (1.01-5.52) 33 (62.3) 20 (37.7) 0.903 1.05 (0.45-2.48) 
GG 33 (53.2) 29 (46.8)  1.00 38 (61.3) 24 (38.7)  1.00 
GA+AA 72 (42.1) 99 (57.9) 0.041 2.16 (1.03-4.53) 118 (69.0) 53 (31.0) 0.316 0.67 (0.30-1.47) 
GENETIC RISK INDEXES 
Non-RespGRI 
Clinical Response 
Response Non-response p OR (95%CI) 
Index 0 rs1805087 – AG+GG AND rs1801394 – GG 10 (55.6) 8 (44.4)  1.00 
Index 1 rs1805087 – AA OR 1801394 – GA+AA 52 (51.5) 49 (48.5) 0.753 1.24 (0.34-4.67) 
Index 2 rs1805087 – AA AND rs1801394 – GA+AA 43 (37.7) 71 (62.3) 0.018 5.68 (1.35-23.87) 
Results are expressed in n (%). p ≤0.05 was considered as statistically significant (highlighted in bold). Multivariate analysis was adjusted 
to following variables: 1) patient-related: age, gender, smoking status and renal function; 2) disease-related: diagnosis age and disease 
duration; and, 3) treatment-related: folic acid, corticosteroids, NSAIDs, other DMARDs and MTX administration characteristics (dose, 
treatment duration and administration route). ToxGRI was not performed because genotypes from studied SNPs for methionine pathway 
did not revealed to be statistically significant with MTX-related toxicity a) When reference was G carriers: OR=2.40, 95%CI: 1.17-4.96. A: 
adenine; CI: confidence interval; DMARDs: disease modifying anti-rheumatic drugs; G: guanine; MS: methionine synthase; MTRR: 
methionine synthase reductase; MTX: methotrexate; Non-RespGRI: genetic risk index for non-response; NSAIDs: non-steroidal anti-
inflammatory drugs; OR: odds ratio; ToxGRI: genetic risk index for MTX-toxicity. 
 
 
De novo purines synthesis pathway: Table 5 represents the relation between MTX therapeutic 
outcome and SNPs in ATIC and GART by genotype-, haplotype- and genetic risk index-based 
approaches. Considering genotype approach, 4 SNPs in ATIC were associated with about 3-fold 
increased risk for MTX non-response: rs2372536 C carriers, rs4673993 T carriers, rs7563206 T carriers 
and rs12995526 T carriers. For haplotype approach, CGTTT haplotype for ATIC combination 1 was 
associated with an increased risk for MTX non-response when compared to GGCCC haplotype. Non-
RespGRI from de novo purines synthesis pathway demonstrated that patients with Index 4 (ATIC 
rs2372536 C carriers + ATIC rs4673993 T carriers + ATIC rs7563206 T carriers + ATIC rs12995526 T 
carriers) presented more than 5-fold increased risk for MTX non-response when compared to those 
with Index 0. Four SNPs in ATIC were associated with about 2-fold increased risk for MTX-related 
toxicity: rs2372536 G carriers, rs3821353 T carriers, rs7563206 C homozygotes and rs12995526 C 
homozygotes. Regarding haplotype approach, CTTCC haplotype for ATIC combination 1 presented an 
increased risk for MTX-related toxicity when compared to CGTTT haplotype. No statistically significant 
associations were observed for ATIC rs16853834 and GART rs8971 with MTX therapeutic outcome. 
ToxGRI demonstrated that patients with Index 4 (ATIC rs2372536 G carriers + ATIC rs3821353 T 
carriers + ATIC rs7563206 CC + ATIC rs12995526 CC) presented more than 15-fold increased risk for 
ADRs occurrence then those with Index 0. 
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Table 5. Association of SNPs involved in De Novo Purines Synthesis Pathway with MTX Therapeutic Outcome  
 Clinical Response Overall Toxicity 
 Response Non-response p OR (95%CI) Non-toxicity Toxicity p OR (95%CI) 
GENOTYPES 
ATIC C>G (rs2372536)  
CC+CG 88 (42.1) 121 (57.9)  1.00 141 (67.5) 68 (32.5)  1.00 
GG 17 (70.8) 7 (29.2) 0.036 0.27 (0.08-0.92) a) 15 (62.5) 9 (37.5) 0.580 0.71 (0.21-2.41) 
CC 47 (42.7) 63 (57.3)  1.00 77 (70.0) 33 (30.0)  1,00 
CG+GG 58 (47.2) 65 (52.8) 0.568 0.83 (0.43-1.59) 79 (64.2) 44 (35.8) 0.050 2.09 (1.00-4.38) 
ATIC G>T (rs3821353)  
GG+GT 96 (45.3) 116 (54.7)  1.00 142 (67.0) 70 (33.0)  1.00 
TT 9 (42.9) 12 (57.1) 0.868 0.91 (0.29-2.86) 14 (66.7) 7 (33.3) 0.766 0.83 (0.25-2.79) 
GG 72 (43.4) 94 (56.6)  1.00 116 (69.9) 50 (30.1)  1.00 
GT+TT 33 (49.3) 34 (50.7) 0.071 0.51 (0.25-1.06) 40 (59.7) 27 (40.3) 0.046 2.18 (1.01-4.71) 
ATIC T>C (rs4673993)  
TT+TC 88 (42.1) 121 (57.9)  1.00 141 (67.5) 68 (32.5)  1.00 
CC 17 (70.8) 7 (29.2) 0.036 0.27 (0.08-0.92) b) 15 (62.5) 9 (37.5) 0.580 0.71 (0.21-2.41) 
TT 48 (43.6) 62 (56.4)  1.00 76 (69.1) 34 (30.9)  1.00 
TC+CC 57 (46.3) 66 (53.7) 0.950 0.98 (0.51-1.89) 80 (65.0) 43 (35.0) 0.194 1.61 (0.78-3.31) 
ATIC T>C (rs7563206)  
TT+TC 66 (37.9) 108 (62.1)  1.00 125 (71.8) 49 (28.2)  1.00 
CC 39 (66.1) 20 (33.9) <0.001 0.20 (0.09-0.46) c) 31 (52.5) 28 (47.5) 0.010 3.06 (1.31-7.12) 
TT 29 (44.6) 36 (55.4)  1.00 45 (69.2) 20 (30.8)  1.00 
TC+CC 76 (45.2) 92 (54.8) 0.558 0.81 (0.40-1.65) 111 (66.1) 57 (33.9) 0.147 1.84 (0.81-4.18) 
ATIC T>C (rs12995526)   
TT+TC 69 (39.0) 108 (61.0)  1.00 126 (71.2) 51 (28.8)  1.00 
CC 36 (64.3) 20 (35.7) 0.001 0.23 (0.10-0.53) d) 30 (53.6) 26 (46.4) 0.013 2.96 (1.26-6.95) 
TT 29 (43.3) 38 (56.7)  1.00 47 (70.1) 20 (29.9)  1.00 
TC+CC 76 (45.8) 90 (54.2) 0.413 0.74 (0.37-1.51) 109 (65.7) 57 (34.3) 0.106 1.97 (0.87-4.49) 
ATIC C>T (rs16853834) 
CC+CT 102 (44.7) 126 (55.3)  1.00 154 (67.5) 74 (32.5)  1.00 
TT 3 (60.0) 2 (40.0) 0.595 1.76 (0.22-14.30) 2 (40.0) 3 (60.0) 0.902 1.14 (0.13-9.68) 
CC 74 (46.2) 86 (53.8)  1.00 105 (65.6) 55 (34.4)  1.00 
CT+TT 31 (42.5) 41 (57.5) 0.438 1.32 (0.65-2.68) 51 (69.9) 22 (30.1) 0.084 0.48 (0.21-1.10) 
GART A>G (rs8971) 
AA+AG 95 (44.4) 119 (55.6)  1.00 144 (67.3) 70 (32.7)  1.00 
GG 10 (52.6) 9 (47.4) 0.540 0.69 (0.21-2.26) 12 (63.2) 7 (36.8) 0.336 0.52 (0.14-1.96) 
AA 54 (42.2) 74 (57.8)  1.00 85 (66.4) 43 (33.6)  1.00 
AG+GG 51 (48.6) 54 (51.4) 0.164 0.62 (0.32-1.21) 71 (67.6) 34 (32.4) 0.513 1.27 (0.62-2.61) 
Results are expressed in n (%). p ≤0.05 was considered as statistically significant (highlighted in bold). Multivariate analysis was adjusted 
to following variables: 1) patient-related: age, gender, smoking status and renal function; 2) disease-related: diagnosis age and disease 
duration; and, 3) treatment-related: folic acid, corticosteroids, NSAIDs, other DMARDs and MTX administration characteristics (dose, 
treatment duration and administration route). *Rare haplotypes (estimated haplotype frequency <2.0%) were excluded from analysis. a) 
When reference was GG genotype, OR=3.66, 95%CI: 1.09-12.33. b) When reference was CC genotype, OR=3.66, 95%CI: 1.09-12.33. 
c) When reference was CC genotype, OR=4.93, 95%CI: 2.15-11.29. d) When reference was CC genotype, OR=4.29, 95%CI: 1.89-9.76. 
A: adenine; ATIC: 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase; C: cytosine; CI: confidence interval; DMARDs: 
disease modifying anti-rheumatic drugs; G: guanine; GART: glycineamide ribonucleotide formyl transferase; MTX: methotrexate; Non-
RespGRI: genetic risk index for non-response; NSAIDs: non-steroidal anti-inflammatory drugs; OR: odds ratio; T: thymine; ToxGRI: 
genetic risk index for MTX-toxicity. 
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Table 5. Association of SNPs involved in De Novo Purines Synthesis Pathway with MTX Therapeutic Outcome 
(cont.) 
HAPLOTYPES 
ATIC C>G 
(rs2372536) 
ATIC G>T 
(rs3821353) 
ATIC T>C 
(rs4673993) 
ATIC T>C 
(rs7563206) 
ATIC T>C 
(rs12995526) 
% * 
Clinical Response Overall Toxicity 
p OR (95%CI) p OR (95%CI) 
C G T T T 48.1  1.00  1.00 
G G C C C 31.1 0.023 0.46 (0.23-
0.89) 
0.150 1.56 (0.85-2.85) 
C T T C C 15.9 0.062 0.51 (0.26-
1.03) 
0.019 2.38 (1.16-4.88) 
C T T T T 3.0 1.000 1.00 (0.23-
4.31) 
0.390 0.48 (0.09-2.49) 
ATIC C>G 
(rs2372536) 
ATIC T>C 
(rs4673993) 
ATIC T>C 
(rs7563206) 
ATIC T>C 
(rs12995526) 
ATIC C>T 
(rs16853834) 
     
C T T T C 34.6  1.00  1.00 
G C C C C 31.1 0.076 0.58 (0.31-
1.96) 
0.200 1.53 (0.80-2.93) 
C T T T T 16.5 0.810 0.92 (0.44-
1.89) 
0.610 0.81 (0.36-1.80) 
C T C C C 16.1 0.063 0.58 (0.33-
1.03) 
0.054 2.04 (0.99-4.21) 
GENETIC RISK INDEXES 
Non-RespGRI 
Clinical Response 
Response Non-
response 
p OR (95%CI) 
Index 0 rs2372536 – GG AND rs4673993 – CC AND rs7563206 – CC 
AND rs12995526 – CC 
17 (70.8) 7 (29.2)  1.00 
Index 1 rs2372536 – CC+CG OR rs4673993 – TT+TC OR rs7563206 
– TT+TC OR rs12995526 – TT+TC 
0 (0.0) 0 (0.0) - - 
Index 2 [rs2372536 – CC+CG AND rs4673993 – TT+TC] OR 
[rs2372536 – CC+CG AND rs7563206 – TT+TC] OR 
[rs2372536 – CC+CG AND rs12995526 – TT+TC] OR 
[rs4673993 – TT+TC AND rs7563206 – TT+TC] OR 
[rs4673993 AND rs12995526 – TT+TC] OR [rs7563206 – 
TT+TC AND rs12995526 – TT+TC] 
19 (59.4) 13 (40.6) 0.219 0.25 (0.03-2.28) 
Index 3 [rs2372536 – CC+CG AND rs4673993 – TT+TC AND 
rs7563206 – TT+TC] OR [rs2372536 – CC+CG AND 
rs4673993 – TT+TC AND rs12995526 – TT+TC] OR 
[rs2372536 – CC+CG AND rs7563206 – TT+TC AND 
rs12995526 – TT+TC] OR [rs4673993 – TT+TC AND 
rs7563206 – TT+TC AND rs12995526 – TT+TC] 
3 (100.0) 0 (0.0) 0.999 1.00 (1.00-1.00) 
Index 4 rs2372536 – CC+CG AND rs4673993 – TT+TC AND 
rs7563206 – TT+TC AND rs12995526 – TT+TC 
66 (37.9) 108 (62.1) 0.013 5.23 (1.41-19.30) 
ToxGRI 
Overall Toxicity 
Non-
toxicity 
Toxicity p OR (95%CI) 
Index 0 rs2372536 – CC AND rs3821353 – GG AND rs7563206 – TT+TC 
AND rs12995526 – TT+TC 
47 (70.1) 20 (29.9)  1.00 
Index 1 rs2372536 – CG+GG OR rs3821353 – GT+TT OR rs7563206 – 
CC OR rs12995526 – CC 
78 (72.9) 29 (27.1) 0.548 1.32 (0.53-3.26) 
Index 2 [rs2372536 – CG+GG AND rs3821353 – GT+TT] OR [rs2372536 
– CG+GG AND rs7563206 – CC] OR [rs2372536 – CG+GG AND 
rs12995526 – CC] OR [rs3821353 – GT+TT AND rs7563206 – 
CC] OR [rs3821353 – GT+TT AND rs12995526 – CC] OR 
[rs7563206 – CC AND rs12995526 – CC] 
1 (33.3) 2 (66.7) 0.999 1.00 (1.00-1.00) 
Index 3 [rs2372536 – CG+GG AND rs3821353 – GT+TT AND rs7563206 
– CC] OR [rs2372536 – CG+GG AND rs3821353 – GT+TT AND 
rs12995526 – CC] OR [rs2372536 – CG+GG AND rs7563206 – 
CC AND rs12995526 – CC] OR [rs3821353 – GT+TT AND 
rs7563206 – CC AND rs12995526 – CC] 
15 (62.5) 9 (37.5) 0.261 2.40 (0.52-11.02) 
Index 4 rs2372536 – CG+GG AND rs3821353 – GT+TT AND rs7563206 
– CC AND rs12995526 – CC 
15 (46.9) 17 (53.1) 0.001 15.60 (3.06-
79.48) 
Results are expressed in n (%). p ≤0.05 was considered as statistically significant (highlighted in bold). Multivariate analysis was adjusted 
to following variables: 1) patient-related: age, gender, smoking status and renal function; 2) disease-related: diagnosis age and disease 
duration; and, 3) treatment-related: folic acid, corticosteroids, NSAIDs, other DMARDs and MTX administration characteristics (dose, 
treatment duration and administration route). *Rare haplotypes (estimated haplotype frequency <2.0%) were excluded from analysis. a) 
When reference was GG genotype, OR=3.66, 95%CI: 1.09-12.33. b) When reference was CC genotype, OR=3.66, 95%CI: 1.09-12.33. c) 
When reference was CC genotype, OR=4.93, 95%CI: 2.15-11.29. d) When reference was CC genotype, OR=4.29, 95%CI: 1.89-9.76. A: 
adenine; ATIC: 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase; C: cytosine; CI: confidence interval; DMARDs: 
disease modifying anti-rheumatic drugs; G: guanine; GART: glycineamide ribonucleotide formyl transferase; MTX: methotrexate; Non-
RespGRI: genetic risk index for non-response; NSAIDs: non-steroidal anti-inflammatory drugs; OR: odds ratio; T: thymine; ToxGRI: 
genetic risk index for MTX-toxicity.  
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Adenosine pathway: Table 6 represents the relation between MTX therapeutic outcome and SNPs in 
ADORA2A and AMPD1 by genotype- and haplotype-based approaches. Considering MTX non-
response, no statistically significant associations were observed. Nevertheless, ADORA2A rs2267076 
T homozygotes was associated with about 3-fold increased risk for MTX-related toxicity. Regarding 
haplotype approach, TC haplotype for ADORA2A rs2267076 and rs2298383 demonstrated almost 2-
fold increased risk for MTX-related toxicity when compared to CT haplotype. 
 
Table 6. Association of SNPs involved in Adenosine Pathway with MTX Therapeutic Outcome 
 Clinical Response Overall Toxicity 
 Response Non-response p OR (95%CI) Non-toxicity Toxicity p OR (95%CI) 
GENOTYPES 
ADORA2A C>T (rs2267076)  
CC+CT 90 (44.3) 113 (55.7)  1.00 141 (69.5) 62 (30.5)  1.00 
TT 15 (50.0) 15 (50.0) 0.552 0.73 (0.26-2.04) 15 (50.0) 15 (50.0) 0.025 3.26 (1.16-9.15) 
CC 39 (42.9) 52 (57.1)  1.00 61 (67.0) 30 (33.0)  1.00 
CT+TT 66 (46.5) 76 (53.5) 0.962 1.02 (0.52-2.00) 95 (66.9) 47 (33.1) 0.126 1.83 (0.84-3.99) 
ADORA2A T>C (rs2298383)  
TT+TC 84 (44.9) 103 (55.1)  1.00 127 (67.9) 60 (32.1)  1.00 
CC 21 (45.7) 25 (54.3) 0.525 0.76 (0.33-1.75) 29 (63.0) 17 (37.0) 0.270 1.64 (0.68-3.98) 
TT 34 (44.2) 43 (55.8)  1.00 50 (64.9) 27 (35.1)  1.00 
TC+CC 71 (45.5) 85 (54.5) 0.883 0.95 (0.47-1.91) 106 (67.9) 50 (32.1) 0.124 1.90 (0.84-4.28) 
AMPD1 C>T (rs17602729)  
CC+CT 104 (45.6) 124 (54.4)  1.00 151 (66.2) 77 (33.8)  1.00 
TT 1 (20.0) 4 (80.0) 0.674 1.76 (0.13-
24.58) 
5 (100.0) 0 (0.0) 0.999 1.00 (1.00-1.00) 
CC 78 (43.3) 102 (56.7)  1.00 121 (67.2) 59 (32.8)  1,00 
CT+TT 27 (50.9) 26 (49.1) 0.517 0.77 (0.36-1.68) 35 (66.0) 18 (34.0) 0.583 0.79 (0.35-1.80) 
HAPLOTYPES 
ADORA2AC>T  
(rs2267076) 
ADORA2A T>C 
(rs2298383) 
% * 
Clinical Response Overall Toxicity 
p OR (95%CI) p OR (95%CI) 
C T 56.7  1.00  1.00 
T C 36.9 0.770 0.93 (0.56-1.54) 0.036 1.84 (1.05-3.23) 
C C 6.4 0.660 0.82 (0.34-1.98) 0.360 0.55 (0.15-2.01) 
Results are expressed in n (%). p ≤0.05 was considered as statistically significant (highlighted in bold). Multivariate analysis was adjusted 
to following variables: 1) patient-related: age, gender, smoking status and renal function; 2) disease-related: diagnosis age and disease 
duration; and, 3) treatment-related: folic acid, corticosteroids, NSAIDs, other DMARDs and MTX administration characteristics (dose, 
treatment duration and administration route). Non-RespGRI and ToxGRI were not performed because only one genotype was statistically 
significant for MTX non-response and no statistically significant associations were obtained regarding MTX-related toxicity. *Rare 
haplotypes (estimated haplotype frequency <2.0%) were excluded from analysis. A: adenine; ADORA2A: adenosine receptor A2A; 
AMPD1: adenosine deaminase 1; C: cytosine; CI: confidence interval; DMARDs: disease modifying anti-rheumatic drugs; G: guanine; 
GRI: genetic risk index; MTX: methotrexate; NSAIDs: non-steroidal anti-inflammatory drugs; OR: odds ratio; T: thymine.  
 
Phase II reactions: Table 7 represents the relation between MTX therapeutic outcome and GSTP1 
A>G (rs1695) by genotype-based approach. No statistically significant associations were observed for 
this SNP and MTX therapeutic outcome. 
 
Table 7. Association of SNPs involved in Phase II Reactions with MTX Therapeutic Outcome 
 Clinical Response Overall Toxicity 
 Response Non-response p OR (95%CI) Non-toxicity Toxicity p OR (95%CI) 
GENOTYPES 
GSTP1 A>G (rs1695)  
AA+AG 93 (44.9) 114 (55.1)  1.00 138 (66.7) 69 (33.3)  1.00 
GG 12 (46.2) 14 (53.8) 0.817 0.88 (0.32-2.48) 18 (69.2) 8 (30.8) 0.123 0.39 (0.12-1.29) 
AA 44 (42.7) 59 (57.3)  1.00 75 (72.8) 28 (27.2)  1.00 
AG+GG 61 (46.9) 69 (53.1) 0.288 0.70 (0.36-1.35) 81 (62.3) 49 (37.7) 0.862 1.07 (0.51-2.21) 
Results are expressed in n (%). p ≤0.05 was considered as statistically significant (highlighted in bold). Multivariate analysis was adjusted 
to following variables: 1) patient-related: age, gender, smoking status and renal function; 2) disease-related: diagnosis age and disease 
duration; and, 3) treatment-related: folic acid, corticosteroids, NSAIDs, other DMARDs and MTX administration characteristics (dose, 
treatment duration and administration route). Haplotypes and GRIs were not performed because only one SNP related with Phase II 
reactions was studied. A: adenine; CI: confidence interval; DMARDs: disease modifying anti-rheumatic drugs; G: guanine; GSTP1: human 
glutathione S-transferase P1; GRI: genetic risk index; MTX: methotrexate; NSAIDs: non-steroidal anti-inflammatory drugs; OR: odds ratio; 
T: thymine. 
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Overall Genetic Risk Indexes & Methotrexate Therapeutic Outcome  
Pertaining to MTX non-response risk genotypes, Non-RespGRI consisted in 8 possible combinations: 
MTHFR rs1801131 AA, MTHFR rs1801133 TT, MS rs1805087 AA, MTRR rs1801394 A carriers, ATIC 
rs2372536 C carriers, ATIC rs4673993 T carriers, ATIC rs7563206 T carriers and ATIC rs12995526 T 
carriers. Distribution of overall Non-RespGRI demonstrated an increasingly risk for MTX non-response 
with an increased Non-RespGRI Index (p<0.001) (Figure 2A). Patients with Index 6 to 8, i.e. patients 
with more than 5 risk genotypes for MTX non-response, demonstrated more than 5-fold increased risk 
for developing a non-response profile to MTX when compared to those with Index up to 5 (Figure 2B). 
Regarding MTX-related toxicity risk genotypes, ToxGRI consisted in 5 possible combinations: ATIC 
rs2372536 G carriers, ATIC rs3821353 T carriers, ATIC rs7563206 CC, ATIC rs12995526 CC and 
ADORA2A rs2267076 TT. Distribution of Overall ToxGRI demonstrated an increasingly risk for MTX-
related toxicity occurrence with an increased ToxGRI Index (p=0.002) (Figure 2C). Patients with Index 
3/4, i.e. patients with more than 2 risk genotypes, demonstrated more than 7-fold increased risk for 
developing MTX-related toxicity when compared to those with Index 1/2 (Figure 2D). 
 
 
A) 
 
 
 
 
 
 
 
 
Overall Non-RespGRI for MTX clinical response profile 
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B) 
 
 
 
 
C) 
 
 
 
 
 
 
 
Overall ToxGRI for MTX-related toxicity 
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D) 
 
 
Figure 2. Association of overall genetic risk indexes and methotrexate therapeutic outcome. A) 
Distribution of overall Non-RespGRI, constituted by 8 combinations of risk genotypes for MTX non-response: 
MTHFR rs1801131 AA, MTHFR rs1801133 TT, MS rs1805087 AA, MTRR rs1801394 A carriers, ATIC rs2372536 
C carriers, ATIC rs4673993 T carriers, ATIC rs7563206 T carriers and ATIC rs12995526 T carriers, by clinical 
response profile to MTX. B) Forest plot representing multivariate analysis of the association between overall Non-
RespGRI and clinical response profile to MTX: *p=0.001, OR=4.58, 95%CI: 1.87-11.20. **p<0.001, OR=13.42, 
95%CI: 4.00-44.96. ***p<0.001, OR=6.23, 95%CI: 2.91-13.31. C) Distribution of overall ToxGRI, constituted by 5 
combinations of risk genotypes for MTX-related toxicity: ATIC rs2372536 G carriers, ATIC rs3821353 T carriers, 
rs7563206 CC, ATIC rs12995526 CC and ADORA2A rs2267076 T, by overall MTX-related toxicity. D) Forest plot 
representing multivariate analysis of the association between the overall ToxGRI and overall MTX-related toxicity: 
*p<0.001, OR=7.65, 95%CI: 2.46-23.75. **p<0.001, OR=7.38, 95%CI: 2.42-22.50. 
ADORA2A: adenosine receptor A2A; ATIC: 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase; CI: confidence 
interval; MS: methionine synthase; MTHFR: methylenetetrahydrofolate reductase; MTRR: methionine synthase reductase; 
MTX: methotrexate; Non-RespGRI: genetic risk index for non-response; OR: odds ratio; ToxGRI: genetic risk index for MTX-
toxicity. 
 
DISCUSSION 
 
The present work aims to evaluate selected SNPs in genes encoding for proteins involved in MTX 
pathways as potential predictors of MTX therapeutic outcome in Portuguese RA patients, based on 
genotype-, haplotype- and genetic risk index-based approaches. Haplotype-based approach was 
performed to incorporate allelic heterogeneity, since different genetic polymorphisms  may lead to a 
similar phenotype, which is a blind spot for a coherent genotype-based  approach [56].  
For polyglutamation pathway, results showed that genotypes were not associated with MTX therapeutic 
outcome, in accordance to other studies [57, 58]. Yet, CC haplotype for GGH rs3758149 and 
rs12681874 were associated with non-response when compared to TC haplotype. Literature describes 
no significant associations for rs3758149 and clinical response profile to MTX [19, 58, 59], prompting 
 "Moving towards Personalized Medicine in Rheumatoid Arthritis: Methotrexate Intracellular Pathways and Phase II Reactions as 
Pharmacogenetic Predictors of Methotrexate Therapeutic Outcome" 
 22 
 
DISSERTAÇÃO - MESTRADO INTEGRADO EM MEDICINA   
Artigo de Investigação Médica 
 
Áurea Lima 
more studies to elucidate this, while for rs12681874 the C allele was associated with MTX non-response 
in RA [46], in accordance to the tendency of CC haplotype.  
Considering folate pathway, MTHFR rs1801131 A homozygotes and MTHFR rs1801133 T 
homozygotes were associated with a non-response profile to MTX. MTHFR is responsible for the 
conversion of 5,10-MTHF to 5-MTHF, a carbon donor for the remethylation of homocysteine into 
methionine [60]. MTHFR A1298C (rs1801131) and C677T (rs1801133) were described as the most 
important MTHFR polymorphisms because of their influence in MTHFR activity and, consequently, in 
MTX action mechanism [15, 61]. The rs1801131 A allele has been associated with an increased 
MTHFR activity [62], leading to an increased pool of folates, resulting in a non-response profile to MTX, 
in accordance to our study and literature in RA [45, 63]. Nevertheless, one study associated A allele 
with better response to MTX in RA [64] while others demonstrated non-significant results [59, 65, 66]. 
For MTX-related toxicity, no significant results were observed for this SNP in this study and were 
described in literature for RA [59, 63, 66-70], still some studies demonstrated significant results [57, 71-
73]. Also, T allele for rs1801133 has been described as responsible for a thermolabile form of MTHFR 
with reduced activity [74]. Despite this functional impact, all studies with significant results concerning 
this SNP in RA demonstrated an association of T allele with non-response to MTX [4, 19, 59, 64], were 
in accordance to present study. Concerning MTX-related toxicity, we demonstrated non-significant 
results for this SNP, as demonstrated in other studies in RA [57, 70]. Moreover, no significant 
associations were observed for DHFR polymorphisms (rs7387, rs1232027, rs1643657 and 
rs10072026) and MTHFS rs8923 with MTX therapeutic outcome. For DHFR polymorphisms, literature 
confirms our results for rs1232027 [64] while for rs1643657 and rs10072026, studies are in agreement 
only regarding to clinical response profile to MTX [46]. For rs7387, our results are different from those 
of Sharma et al. [41], probably due to ethnic differences of population. Regarding haplotype approach, 
associations were not statistically significant, prompting for more studies to elucidate DHFR and 
MTHFR polymorphisms role in MTX therapeutic outcome. Also, to the best of our knowledge, this is the 
first study to analyze the association of MTHFS rs8923 with MTX therapeutic outcome.  
In relation to methionine pathway, MS rs1805087 A homozygotes and MTRR rs1801394 A carriers 
were associated with a non-response profile to MTX. MS (also known as methyltransferase - MTR) 
mediates the conversion of 5-MTHF to THF in the presence of methyl(III)cobalamin, which occurs 
simultaneously with the addition of a methyl group to homocysteine, forming methionine [60, 75]. The 
MTRR maintains adequate levels of methylcob(III)alamin for the reaction mediated by MS occurs [76]. 
Despite the A alleles for MS rs1805087 (A2756G) and MTRR rs1801394 (A66G) have been described 
as responsible for increasing enzyme activity [77, 78], literature demonstrated no significant 
associations of these polymorphisms with MTX therapeutic outcome in RA [39, 40, 42, 45]. Since we 
demonstrated associations of these SNPs with clinical response profile to MTX, more studies are 
necessary to elucidate this. 
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Considering de novo purine synthesis, ATIC rs2372536 C carriers, rs4673993 T carriers, rs7563206 T 
carriers and rs12995526 T carriers were associated with a non-response profile to MTX. ATIC is 
responsible for the conversion of AICAR into FAICAR [4]. The rs2372536 is the most studied ATIC 
polymorphism. Although the effect of this SNP on ATIC activity still unknown, one study in RA 
associated C homozygotes with better response [39] while other more recent studies demonstrated 
non-significant associations [40-42, 44-46, 79], prompting for more studies to address this issue. 
Despite unknown functional impact, T alleles for rs4673993 and rs7563206 were associated with non-
response in RA [4, 46, 47], confirmed by our results, while T allele for rs12995526 was associated with 
better response [46]. Nevertheless, haplotype approach followed the same tendency of genotype 
approach, where CGTTT haplotype for ATIC combination 1 was associated with a non-response profile 
to MTX when compared to GGCCC haplotype. This renders more relevance of our results regarding 
ATIC and MTX therapeutic outcome, but confirmation from other studies is needed. Regarding MTX-
related toxicity, ATIC rs2372536 G carriers, rs3821353 T carriers, rs7563206 C homozygotes and 
rs12995526 C homozygotes were associated with about 2-fold risk for MTX-related toxicity. For 
rs2372536, all studies with significant results concerning this SNP in RA demonstrated an association 
of G allele with MTX-related toxicity [19, 39, 43, 80], confirmed by our results. Only one study for 
rs3821353, rs7563206 and rs12995526 demonstrated a non-significant association of these SNPs with 
MTX-related toxicity [46], Once more, haplotype approach followed the same tendency of genotype 
approach, where CTTCC haplotype for ATIC combination 1 was associated with MTX-related toxicity 
when compared to CGTTT haplotype. Also, no significant associations were observed for ATIC 
rs16853834 and GART rs8971 with MTX therapeutic outcome. The rs16853834 was previously studied 
by Owen et al., which demonstrated a significant association with clinical response to MTX but not with 
MTX-related toxicity [46] while for GART rs8971, to the best of our knowledge, this is the first study to 
analyze its association with MTX therapeutic outcome.  
For adenosine pathway both genotype- and haplotype-based approaches demonstrated non-significant 
associations for ADORA2A rs2267076, ADORA2A rs2298383 and AMPD1 rs17602729 with clinical 
response profile to MTX. ADORA2A is a member of adenosine receptor group of G-protein-coupled 
receptors, responsible for adenosine transport [30]. Hider et al. studied rs2267076 and rs2298383 and 
demonstrated no association with clinical response to MTX [81], in accordance to our results. AMPD1 
catalyzes the conversion of AMP to IMP [39] and rs17602729 (C34T) seems to generate an AMPD1 
enzyme with lower activity due to the non-synonymous amino acid change at codon 12 [82]. Thus, 
deficiency of AMPD1 could enhance adenosine release [39]. Nevertheless, we and other investigators 
demonstrated no associations with MTX clinical response [41, 42, 44, 46], even though some authors 
demonstrated a better response for T allele [43, 83], prompting for an elucidation of this polymorphism 
impact in MTX clinical response profile. In addition, ADORA2A rs2267076 T homozygotes were 
associated with about 3-fold increased risk for developing overall toxicity to MTX, in accordance to 
literature [81]. Haplotype approach followed the same tendency of genotype approach, where TC 
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haplotype for ADORA2A rs2267076 and rs2298383 demonstrated almost 2-fold increased risk for MTX-
related toxicity when compared to CT haplotype. 
Regarding Phase II reactions, GSTP1 rs1695 was not associated with MTX therapeutic outcome. 
GSTP1 is a phase II reaction enzyme involved in MTX inactivation [31] and, despite the functional 
impact of GSTP1 rs1695 (A313G) [48], studies in RA demonstrated no significant associations of this 
SNP with MTX therapeutic outcome [84, 85], in accordance to our results. 
In order to improve the characterization of the impact of relevant studied SNPs associated with MTX 
non-response and MTX-related toxicity, genetic risk indexes for each pathway and overall genetic risk 
indexes were created. Regarding MTX non-response, Overall Non-RespGRI revealed that patients with 
Indexes 6 to 8 had more than 6-fold increased risk for a non-response profile when compared to patients 
with Indexes 0 to 5. Accordingly to MTX-related toxicity, Overall ToxGRI revealed that patients with 
Indexes 3 and 4 had more than 7-fold increased risk for MTX-related toxicity.  
Besides the potential of our results, we are aware of possible study limitations such sample size and 
study design (single-center retrospective study). In order to minimize potential false positive results, 
multivariate analyses adjusted to variables that could influence the measured outcome were performed. 
Beyond multivariate analyses, other strengths of this study can be highlighted such: 1) studied 
population was homogenous relatively to ethnic origin; 2) population characteristics regarding disease 
gender epidemiology and to diagnosis age were in accordance with other reported studies [86, 87]; 3) 
all genotyping results were manually inspected, 10% of the samples were randomly selected for a 
second analysis and results were 100% concordant; 4) polymorphisms were included only if genotyping 
call rates were superior to 95% and the minor allele frequency was greater than 10.0%; and, 5) having 
included a good number of polymorphisms (thirty-five) in fourteen different genes that encode for 
proteins involved in intracellular pathways and Phase II reactions, many of which had never been 
studied before or present conflicting results regarding therapeutic outcome to MTX compared to other 
studies in RA. To the best of our knowledge, this is the first report regarding the study of the association 
of such amount of polymorphisms with MTX therapeutic outcome in Portuguese RA patients. 
As future perspectives, due to lack or conflicting studies analyzing the impact of the studied SNPs in 
proteins function and/or MTX therapeutic outcome, further evidence is necessary to support the 
interpretation of our results. Since we could not genotype all the selected SNPs due to technical 
limitations of genotyping technique, other techniques should be considered due to the possible 
importance and lack of studies analyzing the SNPs that were excluded. Finally, further studies should 
consider that a possible synergetic effect between MTX and other DMARDs could influence the 
associations between genetic polymorphisms and MTX therapeutic outcome. 
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CONCLUSIONS 
 
From a total of 35 SNPs only 26 were studied to evaluate the influence in MTX therapeutic outcome in 
RA Portuguese patients. From these 26 SNPs, 8 genotypes (MTHFR rs1801131 AA, MTHFR 
rs1801133 TT, MS rs1805087 AA, MTRR rs1801394 A carriers, ATIC rs2372536 C carriers, ATIC 
rs4673993 T carriers, ATIC rs7563206 T carriers and ATIC rs12995526 T carriers) and 3 haplotypes 
(CC for GGH rs3758149 and rs12681874; CGTTT for ATIC combination 1 and CTTTC for ATIC 
combination 2) could be predictors of MTX non-response. In addition, 5 genotypes (ATIC rs2372536 G 
carriers, ATIC rs3821353 T carriers, ATIC rs7563206 CC, ATIC rs12995526 CC and ADORA2A 
rs2267076 T) and 2 haplotypes (CTTCC for ATIC combination 1 and TC for ADORA2A rs2267076 and 
rs2298383) could be predictors of MTX-related toxicity. Interestingly, from the 14 studied genes 
encoding for crucial proteins involved in MTX action mechanism, 6 genes demonstrated to be important 
predictors of MTX therapeutic outcome. Moreover, Non-RespGRI and ToxGRI revealed the importance 
of integrating different risk genotypes to predict MTX therapeutic outcome of each RA patient, which 
was highlighted when Overall Non-RespGRI and ToxGRI were performed for all risk genotypes from 
different genes and pathways. Consequently, genotyping patients according to these genetic markers, 
and analysis by genotype- and haplotype-based approaches, may be helpful to identify which patients 
will not benefit from MTX treatment. Furthermore, proposed Non-RespGRI and ToxGRI highlight the 
importance of using genome patients’ information to develop the field of personalized 
medicine/therapeutics. Nevertheless, and despite the potential of these findings, translation into clinical 
practice requires larger and multicentric studies in order to clearly endorse the utility of the obtained 
results. 
 
SUMMARY POINTS 
 
 MTX therapeutic outcome is a complex phenotype, partly modulated by SNPs (e.g. in genes 
implicated in key MTX pathways). 
 Identifying genetic predictors of MTX therapeutic outcome has great importance for moving 
towards personalized medicine in RA.  
 Eight genotypes and 3 haplotypes could be predictors of MTX non-response: MTHFR 
rs1801131 AA, MTHFR rs1801133 TT, MS rs1805087 AA, MTRR rs1801394 A carriers, ATIC 
rs2372536 C carriers, ATIC rs4673993 T carriers, ATIC rs7563206 T carriers and ATIC 
rs12995526 T carriers; CC for GGH rs3758149 and rs12681874; CGTTT for ATIC combination 
1 and CTTTC for ATIC combination 2. 
 Five genotypes and 2 haplotypes could be predictors of MTX-related toxicity: ATIC rs2372536 
G carriers, ATIC rs3821353 T carriers, ATIC rs7563206 CC, ATIC rs12995526 CC and 
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ADORA2A rs2267076 T; CTTCC for ATIC combination 1 and TC for ADORA2A rs2267076 and 
rs2298383. 
 Genotyping patients and analysis by genotype- and haplotype-based approaches may be 
helpful to identify which patients will not benefit from MTX treatment. 
 Proposed genetic risk indexes (Non-RespGRI, ToxGRI and Overall GRIs) highlight the 
importance of use genome patients’ information to develop the field of personalized 
medicine/therapeutics. Further studies, larger and multicentric, should be develop in order to 
clearly endorse the utility of the obtained results.  
 
 
ABBREVIATIONS LIST 
 
ACR: American College of Rheumatology; ADR: adverse drug reactions; ADOR: G-coupled adenosine 
receptors; AICAR: 5-aminoimidazole-4-carboxamide ribonucleotide; ATIC: 5-aminoimidazole-4-
carboxamide ribonucleotide transformylase; ATP: adenosine triphosphate; cAMP: cyclic adenosine 
monophosphate; CD: cluster of differentiation; CTCAE: Common Terminology Criteria for Adverse 
Events; DAS28: Disease Activity Score in 28 joints; DHFR: dihydrofolate reductase; DMARDs: disease 
modifying anti-rheumatic drugs; eGFR: estimated glomerular filtration rate; EULAR: European League 
Against Rheumatism; FPGS: folylpolyglutamate synthetase; GART: glycineamide ribonucleotide formyl 
transferase; GGH: γ-glutamyl hydrolase; GSTP1: glutathione S-transferase P1; HWE: Hardy-Weinberg 
equilibrium; LD: Linkage disequilibrium; MDRD: Modification of Diet in Renal Disease; Non-RespGRI: 
genetic risk index for non-response; MS: methionine synthase; MTHFD1: methylenetetrahydrofolate 
dehydrogenase 1; MTHFR: methylenetetrahydrofolate reductase; MTHFS: methenyltetrahydrofolate 
synthetase; MTRR: methionine synthase reductase; MTX: methotrexate; MTXPGs: MTX 
polyglutamates; NTs: nucleoside transporters; NSAIDs: non-steroidal anti-inflammatory drugs; PO: per 
os; PPAT: phosphoribosyl pyrophosphate amidotransferase; RA: rheumatoid arthritis; SOC: System 
Organ Class; ToxGRI: genetic risk index for MTX-toxicity. 
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ANEXO 
Descrição da População Alvo de Estudo 
 
Table A1. Clinicopathological variables of population enrolled in the study  
 At event Non-response At event Toxicity 
Patient-related   
Male, n (%)  37 (15.9) 37 (15.9) 
Female, n (%)  196 (84.1) 196 (84.1) 
       Postmenopausal, n (%)  96 (49.0) 101 (51.5) 
Age, mean ± SD, years 51.9 ± 11.9 52.0 (26.0-87.0) 
BMI, median (IQR), Kg/m2  27.1 (18.3-44.2) 26.2 (18.4-43.1) 
Current smokers, n (%)  32 (13.7) 32 (13.7) 
       NPY*, median (IQR) 19.5 (0.8-120.0) 20.1 (0.8-120.0) 
Comorbidity**, n (%)  126 (54.1) 126 (54.1) 
Disease-related    
Diagnosis age, mean ± SD, years  40.3 ± 13.2 40.3 ± 13.2 
Disease duration, median (IQR), years  8.0 (0.5-53.0) 10.0 (0.3-51.0) 
RF positive, n (%)  131 (56.2) 131 (56.2) 
Anti-CCP positive, n (%)  175 (75.1) 175 (75.1) 
ANAs positive, n (%)  66 (28.3) 66 (28.3) 
DAS28, mean ± SD 4.2 ± 1.3 4.1 ± 1.4 
Individual variables - DAS28   
      TJC (out of 28), median (IQR)  4.0 (0.0-27.0) 3.9 (0.0-26.0) 
      SJC (out of 28), median (IQR) 3.0 (0.0-24.1) 3.0 (0.0-24.1) 
      ESR, median (IQR), minutes (1st hour) 18.0 (1.0-92.0) 17.8 (1.0-91.0) 
      Global Health on VAS, median (IQR)  48.0 (0.0-100.0) 47.5 (0.0-100.0) 
HAQ score, median (IQR)  1.25 (0.0-2.9) 1.24 (0.0-2.7) 
      HAQ 0.5, n (%)  39 (16.7) 39 (16.7) 
Treatment-related§   
Symptomatic   
      Corticosteroids, n (%)  188 (80.7) 188 (80.7) 
          Daily dose in prednisolone equivalents, median (IQR), mg 5.0 (0.0-20.0) 5.0 (0.0-20.0) 
      NSAIDs, n (%)  170 (73.0) 170 (73.0) 
Supplements   
      Folic acid#, n (%)  118 (50.6) 118 (50.6) 
DMARDs    
      MTX Monotherapy, n (%)  146 (62.7) 136 (58.4) 
      Combined MTX Therapy – sDMARDs, n (%) 59 (25.3) 44 (18.9) 
      Combined MTX Therapy – bDMARDs, n (%) 28 (12.0) 53 (22.7) 
MTX administration characteristics   
      Dose, median (IQR), mg/week 15.0 (2.5-25.0) 15.0 (2.5-25.0) 
      Treatment duration, median (IQR), months 28.0 (6.0-230.0) 47.0 (1.0-240.0) 
      Per os administration route, n (%) 201 (86.3) 210 (90.1) 
      Subcutaneous administration route, n (%) 32 (13.7) 23 (9.9) 
*NPY = (number of cigarettes smoked per day x number of years smoking)/20. **Comorbidity was defined as the presence of diabetes 
mellitus, hypertension, dyslipidemia and/or cardiac disorders beyond rheumatoid arthritis. §Drugs co-administered with methotrexate 
when clinical response/toxicity to methotrexate was recorded. #Patients with compliance to folic acid supplementation.  
ANAs: antinuclear antibodies; Anti-CCP: anti-cyclic citrullinated peptide; bDMARDs: biological disease-modifying antirheumatic drugs; 
BMI: body mass index; DAS28: disease activity score 28; DMARDs: disease-modifying antirheumatic drugs; ESR: erythrocyte 
sedimentation rate; HAQ: health assessment questionnaire; IQR: interquartile range; MTX: methotrexate; NPY: number of pack years; 
NSAIDs: non-steroidal anti-inflammatory drugs; RF: rheumatoid factor; SD: standard deviation; sDMARDs: synthetic disease-modifying 
antirheumatic drugs; SJC:  swollen joints count; TJC: tender joints count; VAS: visual analog scale.  
 
 
 
 
 
  
 
